Why the IMNN-001 and PARP inhibitor pairing could matter more than the standalone data in ovarian cancer
FDA engagement signals cautious progress for AEON Biopharma Inc. in complex biologics space (NYSE American: AEON)
Read More 5 minute read Pharma Industry News Why VG801 could reshape endpoint strategy in inherited retinal disease development VG801 shows early vision gains in Stargardt disease. Discover how VeonGen Therapeutics is redefining endpoints and regulatory strategy. bySoujanya RaviMarch 28, 2026